As of Aug 31, 2026, Cryo-Cell International, Inc. had total assets of $62.3 million and total liabilities of $78.7 million. Total assets were down 1.4% from a year earlier. Stockholders' equity was negative, at -$16.4 million, because liabilities exceed assets. It held $4.2 million in cash and investments against $8.8 million of total debt, net debt of $4.6 million. The current ratio, current assets divided by current liabilities, was 0.86.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.
| Line |
FY 2026
Aug 31, 2026
|
FY 2025
Nov 30, 2025
|
FY 2024
Nov 30, 2024
|
FY 2023
Nov 30, 2023
|
FY 2022
Nov 30, 2022
|
FY 2021
Nov 30, 2021
|
FY 2020
Nov 30, 2020
|
FY 2019
Nov 30, 2019
|
FY 2018
Nov 30, 2018
|
FY 2017
Nov 30, 2017
|
FY 2016
Nov 30, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash |
1
+437.6%
|
0
-43.1%
|
1
+38.1%
|
0
-76.2%
|
2
-79.4%
|
8
-20.2%
|
10
+58.4%
|
7
+8.3%
|
6
-3.8%
|
6
+79.4%
|
3
-15.7%
|
| Short-term investments |
3
-5.2%
|
3
+1.4%
|
3
+411.2%
|
1
+3158.7%
|
0
-76.6%
|
0
-14.8%
|
0
-90.2%
|
1
+3.2%
|
1
+99.3%
|
0
-29.6%
|
1
+2.3%
|
| Cash and investments |
4
+31.3%
|
3
-5.7%
|
3
+256.7%
|
1
-43.1%
|
2
-79.4%
|
8
-20.2%
|
10
+40.4%
|
7
+7.7%
|
7
+2.9%
|
7
+62.9%
|
4
-13.4%
|
| Receivables |
7
+0.0%
|
7
-6.3%
|
7
+11.1%
|
7
+8.8%
|
6
+15.1%
|
5
-16.9%
|
6
+3.7%
|
6
+3.9%
|
6
+14.5%
|
5
+26.5%
|
4
+32.5%
|
| Inventory |
1
-18.6%
|
0
-37.8%
|
1
-14.5%
|
1
-9.7%
|
1
-7.6%
|
1
-0.7%
|
1
-14.5%
|
1
-14.0%
|
1
+300.7%
|
0
-12.9%
|
0
-24.1%
|
| Total current assets |
13
+12.8%
|
12
-6.3%
|
13
+32.8%
|
9
-1.6%
|
10
-39.1%
|
16
-14.9%
|
19
+20.6%
|
15
+4.3%
|
15
+15.9%
|
13
+41.3%
|
9
-13.0%
|
| Property and equipment, net |
21
-3.1%
|
21
-3.9%
|
22
+4.3%
|
21
+54.4%
|
14
+321.1%
|
3
+96.9%
|
2
-11.1%
|
2
+23.6%
|
1
+69.2%
|
1
-9.9%
|
1
+11.4%
|
| Goodwill |
2
+0.0%
|
2
+0.0%
|
2
+0.0%
|
2
+0.0%
|
2
+0.0%
|
2
+0.0%
|
2
+0.0%
|
2
+0.0%
|
2
|
0
|
0
-100.0%
|
| Total assets |
62
-1.4%
|
62
-4.6%
|
65
+5.6%
|
61
-5.7%
|
65
+7.0%
|
61
+31.3%
|
46
+7.7%
|
43
+1.2%
|
42
+77.3%
|
24
+22.4%
|
20
+0.2%
|
| Liabilities and equity | |||||||||||
| Accounts payable |
2
-7.3%
|
3
+52.5%
|
2
-40.7%
|
3
+97.8%
|
2
+7.8%
|
1
+55.6%
|
1
-30.1%
|
1
+8.5%
|
1
-34.6%
|
2
+29.8%
|
1
+11.8%
|
| Total current liabilities |
15
-16.9%
|
20
-8.4%
|
22
+3.5%
|
21
+7.1%
|
19
-7.6%
|
21
+28.4%
|
16
+6.4%
|
15
-0.0%
|
15
+10.7%
|
14
+6.3%
|
13
+25.8%
|
| Total liabilities |
79
+0.9%
|
80
+3.1%
|
78
+7.8%
|
72
+8.8%
|
66
+17.6%
|
56
+15.6%
|
49
-2.0%
|
50
-2.8%
|
51
+40.9%
|
36
+4.2%
|
35
|
| Stockholders' equity |
-16
-10.5%
|
-19
-40.8%
|
-13
-19.8%
|
-11
-623.7%
|
-2
-136.4%
|
4
+257.0%
|
-3
+61.7%
|
-7
+22.0%
|
-9
+28.8%
|
-13
+18.9%
|
-15
-210.5%
|
| Debt | |||||||||||
| Long-term debt |
8
-1.7%
|
8
-1.5%
|
8
-1.3%
|
9
-1.5%
|
9
+360.0%
|
2
-68.1%
|
6
-33.7%
|
9
-30.8%
|
13
+77.4%
|
7
-25.7%
|
10
|
| Lease liabilities |
1
-43.0%
|
1
-3.1%
|
1
-13.4%
|
1
+76.4%
|
1
-33.8%
|
1
+208.5%
|
0
|
—
|
—
|
—
|
—
|
| Total debt |
9
-6.2%
|
9
-1.6%
|
9
-2.7%
|
10
+3.6%
|
9
+231.1%
|
3
-54.8%
|
6
-30.3%
|
9
-30.8%
|
13
+77.4%
|
7
-25.7%
|
10
+326.9%
|
| Net cash |
-5
+25.7%
|
-6
-0.8%
|
-6
+31.9%
|
-9
-14.1%
|
-8
-238.1%
|
6
+31.1%
|
4
+378.6%
|
-2
+74.9%
|
-6
-945.2%
|
-1
+89.9%
|
-6
-331.3%
|
| Ratios | |||||||||||
| Current ratio |
0.86x
|
0.59x
|
0.58x
|
0.45x
|
0.49x
|
0.75x
|
1.13x
|
1.00x
|
0.96x
|
0.91x
|
0.69x
|
| Debt to equity |
—
|
—
|
—
|
—
|
—
|
0.67x
|
—
|
—
|
—
|
—
|
—
|
| Debt to EBITDA |
7.60x
|
6.31x
|
2.26x
|
—
|
1.69x
|
0.56x
|
0.78x
|
1.64x
|
—
|
—
|
—
|
| Return on equity |
—
|
—
|
—
|
—
|
—
|
49.79%
|
—
|
—
|
—
|
—
|
—
|
| Return on assets |
-3.12%
|
-3.94%
|
0.62%
|
-15.55%
|
4.27%
|
3.43%
|
7.85%
|
5.34%
|
-2.02%
|
9.68%
|
-6.76%
|
| Book value per share |
-2.03
|
-2.31
|
-1.64
|
-1.33
|
-0.18
|
0.49
|
-0.35
|
-0.93
|
-1.14
|
-1.76
|
-2.27
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.
Company profile
- Industry
- Services-Misc Health & Allied Services, NEC (SIC 8090)
- Listed as
- CCEL (NYSE)
- Fiscal year ends
- November 30
- Incorporated in
- DE
- Headquarters
- Oldsmar, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 862692
- Former names
- CRYO CELL INTERNATIONAL INC (until Oct 28, 2026)
Other Services-Misc Health & Allied Services, NEC companies
- Fresenius Medical Care AG FMS
- Davita Inc. DVA
- Sotera Health Co SHC
- Progyny, Inc. PGNY
- agilon health, inc. AGL
- Charming Medical Ltd MCTA
- Viemed Healthcare, Inc. VMD
- Park Dental Partners, Inc. PARK
All 15 Services-Misc Health & Allied Services, NEC companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.